Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
120.14
+0.12 (0.10%)
At close: Aug 13, 2025, 4:00 PM
120.09
-0.05 (-0.04%)
Pre-market: Aug 14, 2025, 9:13 AM EDT
Dada Nexus Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
$1,639,943
Profits / Employee
$358,580
Market Cap
149.07B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 17,600 | -400 | -2.22% |
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
Jan 31, 2015 | 7,000 | 900 | 14.75% |
Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
Jan 31, 2013 | 5,000 | 500 | 11.11% |
Jan 31, 2012 | 4,500 | 500 | 12.50% |
Jan 31, 2011 | 4,000 | 148 | 3.84% |
Jan 31, 2010 | 3,852 | 411 | 11.94% |
Jan 31, 2009 | 3,441 | 462 | 15.51% |
Jan 31, 2008 | 2,979 | 464 | 18.45% |
Jan 31, 2007 | 2,515 | 615 | 32.37% |
Jan 31, 2006 | 1,900 | 246 | 14.87% |
Feb 28, 2005 | 1,654 | 229 | 16.07% |
Feb 27, 2004 | 1,425 | 175 | 14.00% |
Feb 28, 2003 | 1,250 | 250 | 25.00% |
Feb 28, 2002 | 1,000 | 150 | 17.65% |
Feb 28, 2001 | 850 | 90 | 11.84% |
Dec 31, 1999 | 760 | 467 | 159.39% |
Dec 31, 1998 | 293 | 4 | 1.38% |
Dec 31, 1997 | 289 | 41 | 16.53% |
Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GILD News
- 5 days ago - Gilead Sciences shares soar; analysts lift targets on HIV strength and Yeztugo outlook - Invezz
- 5 days ago - Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears - Benzinga
- 6 days ago - These Stocks Are Moving Most Today: Trade Desk, Expedia, Pinterest, Twilio, Gilead Sciences - Barrons
- 6 days ago - Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Gilead Sciences Q2: The New Drug That Could Change Everything - Seeking Alpha
- 6 days ago - Gilead posts flat quarterly profit, raises full-year outlook - Reuters
- 6 days ago - Gilead Sciences Announces Second Quarter 2025 Financial Results - Business Wire
- 6 days ago - How To Earn $500 A Month From Gilead Sciences Stock Ahead Of Q2 Earnings - Benzinga